A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Disclosed are various approaches for determining an animal feed formulation. In some implementations, a system may obtain data that provides characteristics of an animal population located at a site. The system may identify a target growth schedule for the animal population. The system may use a data processing model to predict nutrition requirements for tissue growth in the animal population, using the target growth schedule and the characteristics of the animal population, as the model predicts nutrition requirements based on projected nitrogenous energy requirements for the tissue growth. The system may identify a feed formulation producible from a combination of animal feed ingredients to satisfy the nutrition requirements for tissue growth. The system may generate a data output for use of the feed formulation with the animal population, the data output indicating the identified feed formulation producible from the combination of animal feed ingredients.

The invention encompasses methods for reducing the incidence of hemorrhagic heart disease in livestock.

The invention encompasses methods for reducing the incidence of hemorrhagic heart disease in livestock.

Disclosed in the present application are the use of an Aldo-Keto reductase family 1 member C3 (AKR1C3) inhibitor in the inhibition of lipid droplet generation and the promotion of lipid droplet degradation and in the preparation of a drug for treating or preventing MAFLD, a pharmaceutical composition containing the inhibitor, the use of the inhibitor as a drug for treating diseases associated with an abnormal increase in lipid droplets, a method for inhibiting Aldo-Keto reductase family 1 member C3 (AKR1C3), a method for constructing a gene engineering animal model with MAFLD, etc.

Disclosed in the present application are the use of an Aldo-Keto reductase family 1 member C3 (AKR1C3) inhibitor in the inhibition of lipid droplet generation and the promotion of lipid droplet degradation and in the preparation of a drug for treating or preventing MAFLD, a pharmaceutical composition containing the inhibitor, the use of the inhibitor as a drug for treating diseases associated with an abnormal increase in lipid droplets, a method for inhibiting Aldo-Keto reductase family 1 member C3 (AKR1C3), a method for constructing a gene engineering animal model with MAFLD, etc.

The disclosure relates to a sarcoidosis animal model and methods of inducing sarcoidosis in an animal. The disclosure also relates to methods of producing an in vitro granuloma, and methods of using the sarcoidosis animal model. Disclosed herein are animals comprising one or more granulomas, wherein the one or more granulomas comprise Mycobacterium abscessus cell wall microparticles.

The disclosure relates to a sarcoidosis animal model and methods of inducing sarcoidosis in an animal. The disclosure also relates to methods of producing an in vitro granuloma, and methods of using the sarcoidosis animal model. Disclosed herein are animals comprising one or more granulomas, wherein the one or more granulomas comprise Mycobacterium abscessus cell wall microparticles.

The present disclosure relates generally to methods and test kits for identifying SNPs associated with desirable meat eating quality traits in ovine animals. In particular, the present disclosure relates to a SNP-based diagnostic test and method for identifying ovine animals with desirable fat melting point (FMP), intramuscular fat (IMF) and omega-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs) which are characteristic of Australian White sheep or Lamb (e.g., Tattykeel Australian White Lamb), and the use of those tests and methods in animal breeding programs.

The present disclosure relates generally to methods and test kits for identifying SNPs associated with desirable meat eating quality traits in ovine animals. In particular, the present disclosure relates to a SNP-based diagnostic test and method for identifying ovine animals with desirable fat melting point (FMP), intramuscular fat (IMF) and omega-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs) which are characteristic of Australian White sheep or Lamb (e.g., Tattykeel Australian White Lamb), and the use of those tests and methods in animal breeding programs.